|
1
|
Carmeliet P: Angiogenesis in life, disease
and medicine. Nature. 438:932–936. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cao Y: Antiangiogenic cancer therapy: Why
do mouse and human patients respond in a different way to the same
drug? Int J Dev Biol. 55:557–562. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bergers G and Hanahan D: Modes of
resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ellis LM and Hicklin DJ: Pathways
mediating resistance to vascular endothelial growth factor-targeted
therapy. Clin Cancer Res. 14:6371–6375. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen HX and Cleck JN: Adverse effects of
anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol.
6:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hoefen RJ and Berk BC: The role of MAP
kinases in endothelial activation. Vascul Pharmacol. 38:271–273.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Page C and Doubell AF: Mitogen-activated
protein kinase (MAPK) in cardiac tissues. Mol Cell Biochem.
157:49–57. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Davis RJ: Signal transduction by the JNK
group of MAP kinases. Cell. 103:239–252. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shaulian E and Karin M: AP-1 as a
regulator of cell life and death. Nat Cell Biol. 4:E131–E136. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin A: Activation of the JNK signaling
pathway: Breaking the brake on apoptosis. Bioessays. 25:17–24.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weston CR and Davis RJ: The JNK signal
transduction pathway. Curr Opin Genet Dev. 12:14–21. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hibi M, Lin A, Smeal T, Minden A and Karin
M: Identification of an oncoprotein- and UV-responsive protein
kinase that binds and potentiates the c-Jun activation domain.
Genes Dev. 7:2135–2148. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu J and Lin A: Role of JNK activation in
apoptosis: A double-edged sword. Cell Res. 15:36–42. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Guo L, Zhou X, Dong F, Li L,
Cheng Z, Xu Y, Liang J, Xie Q and Liu J: Dihydroartemisinin induces
endothelial cell anoikis through the activation of the JNK
signaling pathway. Oncol Lett. 12:1896–1900. 2016.PubMed/NCBI
|
|
18
|
Kang YJ, Jeon ES, Song HY, Woo JS, Jung
JS, Kim YK and Kim JH: Role of c-Jun N-terminal kinase in the
PDGF-induced proliferation and migration of human adipose
tissue-derived mesenchymal stem cells. J Cell Biochem.
95:1135–1145. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheng YL, Choi Y, Seow WL, Manzanero S,
Sobey CG, Jo DG and Arumugam TV: Evidence that neuronal Notch-1
promotes JNK/c-Jun activation and cell death following ischemic
stress. Brain Res. 1586:193–202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tu Y: The development of new antimalarial
drugs: Qinghaosu and dihydro-qinghaosu. Chin Med J (Engl).
112:976–977. 1999.PubMed/NCBI
|
|
21
|
White NJ: Qinghaosu (artemisinin): The
price of success. Science. 320:330–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van Hensbroek MB, Onyiorah E, Jaffar S,
Schneider G, Palmer A, Frenkel J, Enwere G, Forck S, Nusmeijer A,
Bennett S, et al: A trial of artemether or quinine in children with
cerebral malaria. N Engl J Med. 335:69–75. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen HH, Zhou HJ, Wang WQ and Wu GD:
Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer
Chemother Pharmacol. 53:423–432. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dong F, Zhou X, Li C, Yan S, Deng X, Cao
Z, Li L, Tang B, Allen TD and Liu J: Dihydroartemisinin targets
VEGFR2 via the NF-kB pathway in endothelial cells to inhibit
angiogenesis. Cancer Biol Ther. 15:1479–1488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou HJ, Wang WQ, Wu GD, Lee J and Li A:
Artesunate inhibits angiogenesis and downregulates vascular
endothelial growth factor expression in chronic myeloid leukemia
K562 cells. Vascul Pharmacol. 47:131–138. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen HH, Zhou HJ and Fang X: Inhibition of
human cancer cell line growth and human umbilical vein endothelial
cell angiogenesis by artemisinin derivatives in vitro. Pharmacol
Res. 48:231–236. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu GD, Zhou HJ and Wu XH: Apoptosis of
human umbilical vein endothelial cells induced by artesunate.
Vascul Pharmacol. 41:205–212. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
D'Alessandro S, Basilico N, Corbett Y,
Scaccabarozzi D, Omodeo-Salè F, Saresella M, Marventano I, Vaillant
M, Olliaro P and Taramelli D: Hypoxia modulates the effect of
dihydroartemisinin on endothelial cells. Biochem Pharmacol.
82:476–484. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ho WE, Peh HY, Chan TK and Wong WS:
Artemisinins: Pharmacological actions beyond anti-malarial.
Pharmacol Ther. 142:126–139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dong F, Tian H, Yan S, Li L, Dong X, Wang
F, Li J, Li C, Cao Z, Liu X and Liu J: Dihydroartemisinin inhibits
endothelial cell proliferation through the suppression of the ERK
signaling pathway. Int J Mol Med. 35:1381–1387. 2015.PubMed/NCBI
|
|
31
|
Guo L, Dong F, Hou Y, Cai W, Zhou X, Huang
AL, Yang M, Allen TD and Liu J: Dihydroartemisinin inhibits
vascular endothelial growth factor-induced endothelial cell
migration by a p38 mitogen-activated protein kinase-independent
pathway. Exp Ther Med. 8:1707–1712. 2014.PubMed/NCBI
|
|
32
|
Pinent M, Hackl H, Burkard TR, Prokesch A,
Papak C, Scheideler M, Hämmerle G, Zechner R, Trajanoski Z and
Strauss JG: Differential transcriptional modulation of biological
processes in adipocyte triglyceride lipase and hormone-sensitive
lipase-deficient mice. Genomics. 92:26–32. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cano E, Hazzalin CA and Mahadevan LC:
Anisomycin-activated protein kinases p45 and p55 but not
mitogen-activated protein kinases ERK-1 and −2 are implicated in
the induction of c-fos and c-jun. Mol Cell Biol. 14:7352–7362.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Z, Meng D, Li G, Xu J, Tian K and Li Y:
Celecoxib combined with diacerein effectively alleviates
osteoarthritis in rats via regulating JNK and p38MAPK signaling
pathways. Inflammation. 38:1563–1572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kohlstedt K, Busse R and Fleming I:
Signaling via the angiotensin-converting enzyme enhances the
expression of cyclooxygenase-2 in endothelial cells. Hypertension.
45:126–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bennett BL, Sasaki DT, Murray BW, O'Leary
EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, et
al: SP600125, an anthrapyrazolone inhibitor of Jun N-terminal
kinase. Proc Natl Acad Sci USA. 98:13681–13686. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cho SG and Choi EJ: Apoptotic signaling
pathways: Caspases and stress-activated protein kinases. J Biochem
Mol Biol. 35:24–27. 2002.PubMed/NCBI
|
|
39
|
Bubici C, Papa S, Pham CG, Zazzeroni F and
Franzoso G: The NF-kappaB-mediated control of ROS and JNK
signaling. Histol Histopathol. 21:69–80. 2006.PubMed/NCBI
|
|
40
|
Liu SF, Ye X and Malik AB: Pyrrolidine
dithiocarbamate prevents I-kappaB degradation and reduces
microvascular injury induced by lipopolysaccharide in multiple
organs. Mol Pharmacol. 55:658–667. 1999.PubMed/NCBI
|
|
41
|
Harris VK, Coticchia CM, Kagan BL, Ahmad
S, Wellstein A and Riegel AT: Induction of the angiogenic modulator
fibroblast growth factor-binding protein by epidermal growth factor
is mediated through both MEK/ERK and p38 signal transduction
pathways. J Biol Chem. 275:10802–10811. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huynh-Do U, Vindis C, Liu H, Cerretti DP,
McGrew JT, Enriquez M, Chen J and Daniel TO: Ephrin-B1 transduces
signals to activate integrin-mediated migration, attachment and
angiogenesis. J Cell Sci. 115:3073–3081. 2002.PubMed/NCBI
|
|
43
|
Liu J and Kapron CM: Differential
induction of MAP kinase signalling pathways by cadmium in primary
cultures of mouse embryo limb bud cells. Reprod Toxicol.
29:286–291. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sakurai T and Kudo M: Signaling pathways
governing tumor angiogenesis. Oncology. 81:(Suppl 1). S24–S29.
2011. View Article : Google Scholar
|
|
45
|
Uchida C, Gee E, Ispanovic E and Haas TL:
JNK as a positive regulator of angiogenic potential in endothelial
cells. Cell Biol Int. 32:769–776. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Aggarwal BB: Tumour necrosis factors
receptor associated signalling molecules and their role in
activation of apoptosis, JNK and NF-kappaB. Ann Rheum Dis.
59:(Suppl 1). i6–i16. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ham J, Eilers A, Whitfield J, Neame SJ and
Shah B: c-Jun and the transcriptional control of neuronal
apoptosis. Biochem Pharmacol. 60:1015–1021. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xia Z, Dickens M, Raingeaud J, Davis RJ
and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases
on apoptosis. Science. 270:1326–1331. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lenczowski JM, Dominguez L, Eder AM, King
LB, Zacharchuk CM and Ashwell JD: Lack of a role for Jun kinase and
AP-1 in Fas-induced apoptosis. Mol Cell Biol. 17:170–181. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu ZG, Hsu H, Goeddel DV and Karin M:
Dissection of TNF receptor 1 effector functions: JNK activation is
not linked to apoptosis while NF-kappaB activation prevents cell
death. Cell. 87:565–576. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tang F, Tang G, Xiang J, Dai Q, Rosner MR
and Lin A: The absence of NF-kappaB-mediated inhibition of c-Jun
N-terminal kinase activation contributes to tumor necrosis factor
alpha-induced apoptosis. Mol Cell Biol. 22:8571–8579. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Papa S, Zazzeroni F, Pham CG, Bubici C and
Franzoso G: Linking JNK signaling to NF-kappaB: A key to survival.
J Cell Sci. 117:5197–5208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
De Smaele E, Zazzeroni F, Papa S, Nguyen
DU, Jin R, Jones J, Cong R and Franzoso G: Induction of gadd45beta
by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature.
414:308–313. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Reuther-Madrid JY, Kashatus D, Chen S, Li
X, Westwick J, Davis RJ, Earp HS, Wang CY and Baldwin AS Jr: The
p65/RelA subunit of NF-kappaB suppresses the sustained,
antiapoptotic activity of Jun kinase induced by tumor necrosis
factor. Mol Cell Biol. 22:8175–8183. 2002. View Article : Google Scholar : PubMed/NCBI
|
